All lobbying filings

Corcoran & Associates, Inc. DBA Corcoran Partners

Corcoran & Associates, Inc. DBA Corcoran Partners filed a Q3 report for Novartis on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for Novartis · Bio-pharmaceutical company

As filed: CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS for NOVARTIS.

All filings by Corcoran & Associates, Inc. DBA Corcoran Partners · Everything Novartis has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Support for H.R. 1672 - Maintaining Investments in New Innovation Act (MINI Act)

Trade (domestic/foreign)

Pharmaceutical market competition

Bills named in this filing 1

H.R. 1672
Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.